We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Plasma Neurofilament Light Predicts All-Cause Mortality Risk

By LabMedica International staff writers
Posted on 21 Jun 2022
Print article
Image: Simoa HD-X Analyzer was used to quantify plasma neurofilament light chain (Photo courtesy of Quanterix)
Image: Simoa HD-X Analyzer was used to quantify plasma neurofilament light chain (Photo courtesy of Quanterix)

Neurofilament light chain (NfL) is a cytoskeletal protein component exclusively expressed in neurons that is released into the extracellular fluids, including blood, during neuroaxonal damage. NfL is linked to mortality in neurological disorders, remaining unexplored in population studies.

NfL reflects sub-cortical large-caliber axonal degeneration. Plasma NfL levels correlate strongly with cerebrospinal fluid (CSF) NfL levels, adding to its clinical utility in differential diagnoses for dementias and other neurodegenerative diseases. Therefore, plasma NfL measurements are advantageous given the invasiveness of CSF assessments and feasibility for long-term monitoring.

Scientists at the National Institute on Aging (Baltimore, MD, USA) collected longitudinal data from 694 participants in the Healthy Aging in Neighborhoods of Diversity Across the Life Span study (HANDLS, mean age first visit [v1]: 47.8 years, 42% male, 55.8% African American). Fasting blood samples were collected between 9:30 am and 11:30 am into EDTA blood collection tubes.

Plasma NfL was measured prospectively at three visits. Plasma NfL levels were quantified using the Simoa NF-light Advantage Kit on a Simoa HD-X analyzer by Quanterix (Billerica, MA, USA). Total cholesterol (mg/dL), HDL cholesterol (mg/dL), high-sensitivity C-reactive protein (hsCRP) (mg/dL), albumin (g/dL), and glycosylated hemoglobin (HbA1c) (%) were quantified by contract laboratories (Quest Diagnostics, Chantilly, VA, USA). In this study, the δNfL is the annualized rate of change between NfLv1, NfLv2, and NfLv3, on average, when these measurements were Loge-transformed.

The team reported that most notably, men had significantly higher plasma NfL (Loge-transformed) compared to women at both visits 1 and 3. These differences remained comparable after further adjustment for age, race, and poverty status. Moreover, men were more likely than women to be pre-diabetic, with the reverse being observed in the case of diabetes. Self-reported history of cardiovascular disease (CVD) was more prevalent in women (15.9% versus 8.7%). Several continuous components of AL were higher among women, namely hsCRP, total cholesterol, and HDL cholesterol, while the reverse was observed for albumin and diastolic blood pressure (DBP). Similar patterns were observed for binary AL components. Notably, NfLv1 was shown to be a better prognostic indicator at normal hsCRP values among women, while HbA1c and δNfL interacted synergistically to determine mortality risk, overall.

The authors concluded that plasma NfL levels measured both at baseline and over time can predict all-cause mortality in women. The study was published on June 13, 2022 in the journal BMC Medicine.

Related Links:
National Institute on Aging 
Quanterix 
Quest Diagnostics 

Gold Member
Rickettsia Conorii Assay
RICKETTSIA CONORII ELISA
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Drug Detection Platform
ABSOLUDY Drug Detection Platform
New
UHF RFID Tag & Inlay
AD-164 U9

Print article

Channels

Molecular Diagnostics

view channel
Image: New Alzheimer’s studies have revealed disease biology, risk for progression, and potential for a novel blood test (Photo courtesy of Adobe Stock)

Novel Blood Test Could Reveal Alzheimer’s Disease Biology and Risk for Progression

The inability to diagnose Alzheimer’s disease, the most prevalent form of dementia in the elderly, at an early stage of molecular pathology is considered a key reason why treatments fail in clinical trials.... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The Accelerate WAVE system delivers rapid AST directly from positive blood culture bottles (Photo courtesy of Accelerate Diagnostics)

Rapid Diagnostic System to Deliver Same-Shift Antibiotic Susceptibility Test Results

The World Health Organization estimates that sepsis impacts around 49 million people worldwide each year, resulting in roughly 11 million deaths, with about 1.32 million of these deaths directly linked... Read more

Pathology

view channel
Image: Virtual birefringence imaging and histological staining of amyloid deposits in label-free tissue (Photo courtesy of Ozcan Research Group)

AI-Based Tissue Staining Detects Amyloid Deposits Without Chemical Stains or Polarization Microscopy

Systemic amyloidosis, a disorder characterized by the buildup of misfolded proteins in organs and tissues, presents significant diagnostic difficulties. The condition affects millions of people each year,... Read more

Industry

view channel
Image: The Scopio X100 and X100HT full-field digital cell morphology solution (Photo courtesy of Beckman Coulter)

Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership

Since 2022, Beckman Coulter (Brea, CA, USA) and Scopio Labs (Tel Aviv, Israel) have been working together to accelerate adoption of the next generation of digital cell morphology. Scopio's X100 and X100HT... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.